Migraine prophylaxis

被引：19

作者：

Stark, Richard J. ^{[1
,2
]}

Stark, Catherine. D. ^{[3
]}

机构：

[1] Alfred Hosp, Melbourne, Vic, Australia

[2] Monash Univ, Melbourne, Vic 3004, Australia

[3] Austin & Repatriat Med Ctr, Melbourne, Vic, Australia

来源：

MEDICAL JOURNAL OF AUSTRALIA | 2008年 / 189卷 / 05期

关键词：

D O I：

10.5694/j.1326-5377.2008.tb02028.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There is a wide array of options for migraine prophylaxis; many of the available drugs are clearly proven to be effective and yet are underused in Australia. "New" drugs which are gaining favour for migraine prophylaxis include topiramate, candesartan, gabapentin and botulinum toxin. The evidence for efficacy is excellent for topiramate and reasonably good but limited for candesartan and gabapentin. The use of botulinum toxin is controversial and has gained substantial popularity through anecdotal experience rather than convincing published evidence. Transformed or chronic migraine with medication overuse is a particularly difficult problem. New strategies to aid in medication withdrawal are reviewed. The approach to menstrual migraine and migraine with prominent aura may differ from that for typical migraine. Novel approaches are being explored for these problems. MJA 2008; 189: 283-288

引用

页码：283 / 288

页数：6

共 42 条

[1]

[Anonymous], 1999, A guide to the development, implementation and evaluation of clinical practice guidelines

[2] Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders [J].

Blumenfeld, A .

HEADACHE, 2003, 43 (08) :853-860

[3] Topiramate for migraine prevention - A randomized controlled trial [J].

Brandes, JL ;

Saper, JR ;

Diamond, M ;

Couch, JR ;

Lewis, DW ;

Schmitt, J ;

Neto, W ;

Schwabe, S ;

Jacobs, D .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (08) :965-973

[4] Levetiracetam in the prophylaxis of migraine with aura: A 6-month open-label study [J].

Brighina, Filippo ;

Palermo, Antonio ;

Aloisio, Antonina ;

Francolini, Margherita ;

Giglia, Giuseppe ;

Fierro, Brigida .

CLINICAL NEUROPHARMACOLOGY, 2006, 29 (06) :338-342

[5] Epidemiology of chronic daily headache in the general population [J].

Castillo, J ;

Muñoz, P ;

Guitera, V ;

Pascual, J .

HEADACHE, 1999, 39 (03) :190-196

[6]

Chronicle E., 2004, COCHRANE DB SYST REV, V3, DOI [10.1002/14651858.CD003226.pub2, DOI 10.1002/14651858.CD003226.PUB2]

[7] Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study [J].

D'Andrea, G ;

Granella, F ;

Cadaldini, M ;

Manzoni, GC .

CEPHALALGIA, 1999, 19 (01) :64-66

[8] Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study [J].

Diener, H-C ;

Bussone, G. ;

Van Oene, J. C. ;

Lahaye, M. ;

Schwalen, S. ;

Goadsby, P. J. .

CEPHALALGIA, 2007, 27 (07) :814-823

[9] Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial [J].

Diener, Hans-Christoph ;

Agosti, Reto ;

Allais, Gianni ;

Bergmans, Paul ;

Bussone, Gennaro ;

Davies, Brendan ;

Ertas, Mustafa ;

Lanteri-Minet, Michel ;

Reuter, Uwe ;

Del Rio, Margarita Sdnchez ;

Schoenen, Jean ;

Schwalen, Susanne ;

van Oene, Joop .

LANCET NEUROLOGY, 2007, 6 (12) :1054-1062

[10] Topiramate in migraine prophylaxis -: Results from a placebo-controlled trial with propranolol as an active control [J].

Diener, HC ;

Tfelt-Hansen, P ;

Dahlöf, C ;

Láinez, MJA ;

Sandrini, G ;

Wang, SJ ;

Neto, W ;

Vijapurkar, U ;

Doyle, A ;

Jacobs, D .

JOURNAL OF NEUROLOGY, 2004, 251 (08) :943-950

← 1 2 3 4 5 →